Real-World Psilocybin Data From 2,363 Oregon and Colorado Users Show Mental Health Gains With Low Adverse Events

The study captured voluntary follow-up data through the Althea platform from participants screened under state rules that permit more individuals than most RCTs, including those with prior substance use or milder comorbidities. Fifty percent traveled from out of state, and 36 percent cited depression or anxiety as primary motivation. Self-reported symptom relief reached levels comparable to the 2022 NEJM psilocybin-for-depression trial, yet the sample included higher baseline variability.

Observational self-report designs cannot isolate placebo effects or confirm causality, and the two-week horizon leaves durability untested. The preprint notes low rates of serious adverse events but does not break out subgroup risks for those recently on lithium or with remote psychotic histories, gaps that clinical protocols explicitly exclude. Funding ties to the platform operator introduce potential reporting bias not present in independent academic trials.

Next steps require linkage to state adverse-event registries and longer-term follow-up through validated clinician-rated scales. Without these, regulators cannot determine whether real-world access expands benefit or merely shifts risk profiles compared with tightly screened RCTs published in JAMA Psychiatry.